Medical DNA Sequencing Leads to Lawsuits and Legal QuestionsApril 29, 2019 |
The genome is static, but our ability to analyze it and interpret it is undergoing dramatic change,” said James Evans, a geneticist at the University of North Carolina in Chapel Hill
Quick Read
A prominent pediatrician and medical researcher in the Philippines has been indicted over the failed—and many say premature—introduction of Dengvaxia, a vaccine against dengue that was yanked from the Philippine market in 2017 because of safety issues
Quick Read
Post-Hong Kong: Human Genome Editing’s Brave New WorldApril 17, 2019 |
Watch now: The NAM & CSIS Commission on Strengthening America’s Health Security hosted a conversation on whether human germline genome editing should be permitted, the types of applications which might be appropriate, the standards and criteria that should be followed, and what regulatory or governance framework is needed. Panel includes our Jeffrey Kahn
Quick Read
Stanford is investigating Stephen Quake, a professor of biotechnology, because of his interaction with He Jiankui, the scientist behind the first gene-edited babies. “I hold myself to high ethical standards,” said Dr. Quake, who was once Dr. He’s academic adviser
Quick Read
OverprescribedApril 3, 2019 |
High cost isn’t America’s only drug problem. The pharmaceutical industry has followed a brilliant two-pronged strategy to maximize its profits: raise prices and increase consumption of medications
Quick Read
Nobel Prize Winner Argues Banning CRISPR Won’t WorkApril 3, 2019 |
A registry could keep human gene editing aboveboard, David Baltimore says
Quick Read
FDA to Update Its Definition of ‘Healthy’ This SummerApril 1, 2019 |
The U.S. Food and Drug Administration plans to release a new definition for the term “healthy” this summer, Commissioner Scott Gottlieb said Friday at an event held by the Pew Charitable Trusts in Washington, DC
Quick Read
The international committee of 18 researchers and bioethicists, which met in Geneva, Switzerland, over the past 2 days, also agreed with the widespread consensus that it would be “irresponsible at this time for anyone to proceed with clinical applications of human germline genome editing.”
Quick Read
